The Effect of Sirolimus on the Pharmacokinetics of Tacrolimus

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2003 by National Taiwan University Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT00166829
First received: September 12, 2005
Last updated: March 7, 2007
Last verified: August 2003

September 12, 2005
March 7, 2007
May 2004
Not Provided
The influence of sirolimus on the pharmacokinetics of tacrolimus in renal transplant patients
Same as current
Complete list of historical versions of study NCT00166829 on ClinicalTrials.gov Archive Site
Compare the outcome of tacrolimus/sirolimus and tacrolimus/mycophenolate in rejection prevention
Same as current
Not Provided
Not Provided
 
The Effect of Sirolimus on the Pharmacokinetics of Tacrolimus
The Effect of Sirolimus on the Pharmacokinetics of Tacrolimus

The purpose of this study is to understand whether the pharmacokinetics of tacrolimus is influenced by the concurrent use of sirolimus.

The controlled clinical trial held in NTUH in 2001 revealed that the bioavailability of tacrolimus when combined with sirolimus is lower than that reported in the literature where tacrolimus was not combined with sirolimus. To determine if the difference was due to the drug interaction between sirolimus and tacrolimus, a controlled clinical trial was proposed.

The purpose of this study is to understand whether the pharmacokinetics of tacrolimus is influenced by the concurrent use of sirolimus.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Kidney Transplantation
Drug: sirolimus, tacrolimus, mycophenolate mofetil
Not Provided
Tsai MK, Wu FL, Lai IR, Lee CY, Hu RH, Lee PH. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy. Int J Artif Organs. 2009 Jun;32(6):371-80.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
Not Provided
Not Provided

Inclusion Criteria:

  • De novo kidney transplant patients
  • Aged 13 - 65 years
  • Having aminotransferase concentrations within 2 times the upper limit of normal

Exclusion Criteria:

  • Pregnancy
  • Tuberculosis
  • Hepatitis B or C carrier status
  • Human immunodeficiency virus-positive status
  • Retransplantation or multi-organ transplantation
  • History of rheumatoid arthritis
Both
13 Years to 65 Years
No
Contact: Meng-Kun Tsai, MD, PhD 886-2-23123456 ext 5622 mark9@ha.mc.ntu.edu.tw
Contact: Fe-Lin L Wu, PhD 886-2-23123456 ext 8389 flwu@ha.mc.ntu.edu.tw
Taiwan
 
NCT00166829
920606
Not Provided
Not Provided
National Taiwan University Hospital
Not Provided
Study Chair: Po-Huang Lee, MD, PhD National Taiwan University Hospital
National Taiwan University Hospital
August 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP